Arexis AB

Sweden

Back to Profile

1-12 of 12 for Arexis AB Sort by
Query
Aggregations
IP Type
        Trademark 7
        Patent 5
Jurisdiction
        United States 8
        Europe 2
        World 2
Date
2025 1
2024 1
2023 1
Before 2021 9
IPC Class
A61K 39/00 - Medicinal preparations containing antigens or antibodies 3
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses 3
A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus 2
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses 2
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof 2
See more
NICE Class
05 - Pharmaceutical, veterinary and sanitary products 5
42 - Scientific, technological and industrial services, research and design 3
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services 3
36 - Financial, insurance and real estate services 2
41 - Education, entertainment, sporting and cultural services 2
See more

1.

Miscellaneous Design

      
Application Number 1879299
Status Registered
Filing Date 2025-04-21
Registration Date 2025-04-21
Owner Arexis AB (Sweden)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders. Medical services; medical information services; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders; medical consulting services in the field of genetic diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of genetic diseases and disorders, via an online database that collects data and information on genetic diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of genetic diseases and disorders; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; medical consulting services in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, via an online database that collects data and information on cardiovascular, metabolic, neurological and inflammatory diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of cardiovascular, metabolic, neurological and inflammatory diseases and disorders.

2.

TRYNGOLZA

      
Application Number 1822011A
Status Registered
Filing Date 2024-04-15
Registration Date 2024-04-15
Owner Arexis AB (Sweden)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders. Education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders, online journals, namely, blogs featuring information on genetic diseases and disorders; education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, online journals, namely, blogs featuring information on diseases and disorders of the cardiovascular, metabolic, neurological and inflammatory diseases and disorders. Pharmaceutical research and development in the field of genetic diseases and disorders, providing medical and scientific research and medical and scientific research information in the field of genetic diseases and disorders, research in the field of genetic diseases and disorders; pharmaceutical research and development in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, providing medical and scientific research and medical and scientific research information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, research in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders. Medical services; medical information services; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders; medical consulting services in the field of genetic diseases and disorders; healthcare services, namely, providing medical and healthcare information via an online database in the field of genetic diseases and disorders; providing medical and healthcare information concerning the screening, diagnosis, and treatment of genetic diseases and disorders; providing medical and healthcare information via a website for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; medical consulting services in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; healthcare services, namely, providing medical and healthcare information via an online database in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; providing medical and healthcare information concerning the screening, diagnosis, and treatment of cardiovascular, metabolic, neurological and inflammatory diseases and disorders.

3.

TRYNGOLZA

      
Application Number 018960019
Status Registered
Filing Date 2023-12-05
Registration Date 2024-04-16
Owner Arexis AB (Sweden)
NICE Classes  ?
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 41 - Education, entertainment, sporting and cultural services
  • 42 - Scientific, technological and industrial services, research and design
  • 44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services

Goods & Services

Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of cardiovascular, metabolic, neurological, and inflammatory diseases and disorders; pharmaceuticals; pharmaceutical preparations. Education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders, online journals, namely, blogs featuring information on genetic diseases and disorders; education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, online journals, namely, blogs featuring information on diseases and disorders of the cardiovascular, metabolic, neurological and inflammatory diseases and disorders. Pharmaceutical research and development in the field of genetic diseases and disorders, providing medical and scientific research and medical and scientific research information in the field of genetic diseases and disorders, compiling data for research purposes in the field of genetic diseases and disorders; pharmaceutical research and development in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, providing medical and scientific research and medical and scientific research information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, compiling data for research purposes in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders. Medical services; medical information services; providing a website featuring medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the field of genetic diseases and disorders; medical consulting services in the field of genetic diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of genetic diseases and disorders, and collecting data and information on genetic diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of genetic diseases and disorders; providing a website featuring medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; medical consulting services in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders; healthcare services, namely, providing an online database of medical and healthcare information in the field of cardiovascular, metabolic, neurological and inflammatory diseases and disorders, and collecting data and information on cardiovascular, metabolic, neurological and inflammatory diseases and disorders for treatment and diagnostic purposes; providing medical and healthcare information concerning the screening, diagnosis, and treatment of cardiovascular, metabolic, neurological and inflammatory diseases and disorders.

4.

SYNAGIS CONNECT

      
Serial Number 88481687
Status Registered
Filing Date 2019-06-20
Registration Date 2021-01-05
Owner AREXIS AB (Sweden)
NICE Classes  ? 36 - Financial, insurance and real estate services

Goods & Services

Patient support program, namely, providing information about eligibility for financial assistance provided through patient benefits programs

5.

SYNAGIS CONNECT

      
Serial Number 88481636
Status Registered
Filing Date 2019-06-20
Registration Date 2021-01-05
Owner AREXIS AB (Sweden)
NICE Classes  ? 36 - Financial, insurance and real estate services

Goods & Services

Patient support program, namely, providing information about eligibility for financial assistance provided through patient benefits programs

6.

Manufacturing method

      
Application Number 15522472
Grant Number 10625180
Status In Force
Filing Date 2015-10-30
First Publication Date 2017-11-23
Grant Date 2020-04-21
Owner Arexis AB (Sweden)
Inventor
  • Choudhary, Sureshkumar
  • Mezghebe, Tesfu
  • Houchin, Mary
  • Vernooij, Eric
  • Peters, Marjo
  • Corcoran, Marta
  • Kim, Yoen Joo
  • Cao, Mingyan

Abstract

This application is directed to a method of producing vials containing a composition comprising a recombinant protein. In some embodiments, the method comprises: (a) providing a container containing a composition comprising a recombinant protein optionally where the container has been stored under positive pressure; (b) applying a vacuum to the container containing a composition comprising a recombinant protein; (c) allowing the vacuum to degas the composition; and (d) filling vials with the de gassed composition comprising a recombinant protein.

IPC Classes  ?

  • B01D 19/00 - Degasification of liquids
  • C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
  • C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

7.

Antibodies against and methods for producing vaccines for respiratory syncytial virus

      
Application Number 14479612
Grant Number 09499590
Status In Force
Filing Date 2014-09-08
First Publication Date 2015-05-07
Grant Date 2016-11-22
Owner AREXIS AB (Sweden)
Inventor
  • Mcauliffe, Josephine
  • Palmer-Hill, Frances
  • Zhu, Qing
  • Suzich, Joann

Abstract

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

IPC Classes  ?

  • C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
  • C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies
  • G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

8.

Antibodies against and methods for producing vaccines for respiratory syncytial virus

      
Application Number 13147051
Grant Number 08852608
Status In Force
Filing Date 2009-12-23
First Publication Date 2012-06-21
Grant Date 2014-10-07
Owner AREXIS AB (Sweden)
Inventor
  • Mcauliffe, Josephine
  • Palmer-Hill, Frances
  • Zhu, Qing
  • Suzich, Joann

Abstract

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

IPC Classes  ?

  • A61K 39/155 - Paramyxoviridae, e.g. parainfluenza virus
  • A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
  • C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
  • C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
  • C12N 7/08 - Inactivation or attenuationProducing viral sub-units by serial passage of virus
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

9.

Antibodies against and methods for producing vaccines for respiratory syncytial virus

      
Application Number 12718476
Grant Number 09096658
Status In Force
Filing Date 2010-03-05
First Publication Date 2010-11-04
Grant Date 2015-08-04
Owner AREXIS AB (Sweden)
Inventor
  • Tous, Guillermo
  • Schenerman, Mark
  • Casas-Finet, Jose
  • Wei, Ziping
  • Pfarr, David

Abstract

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

IPC Classes  ?

  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
  • G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies
  • C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
  • C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
  • A61K 39/00 - Medicinal preparations containing antigens or antibodies

10.

Antibodies against and methods for producing vaccines for respiratory syncytial virus

      
Application Number 11230593
Grant Number 07700720
Status In Force
Filing Date 2005-09-21
First Publication Date 2006-05-11
Grant Date 2010-04-20
Owner AREXIS AB (Sweden)
Inventor
  • Tous, Guillermo
  • Schenerman, Mark
  • Casas-Finet, Jose
  • Wei, Ziping
  • Pfarr, David

Abstract

The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.

IPC Classes  ?

11.

AREXIS

      
Application Number 004294328
Status Registered
Filing Date 2005-02-17
Registration Date 2006-10-06
Owner Arexis AB (Sweden)
NICE Classes  ?
  • 03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
  • 05 - Pharmaceutical, veterinary and sanitary products
  • 42 - Scientific, technological and industrial services, research and design

Goods & Services

Cosmetics; cosmetic preparations for skin care. Pharmaceutical preparations, not including pharmaceutical preparations for the treatment of diseases of the central nervous system; sanitary preparations for medical purposes; dietetic substances adapted for medical use; food for babies. Scientific and technological services and research and design relating thereto; licensing of intellectual property.

12.

SYNAGIS

      
Serial Number 75408414
Status Registered
Filing Date 1997-12-19
Registration Date 1999-05-25
Owner AREXIS AB (Sweden)
NICE Classes  ?
  • 01 - Chemical and biological materials for industrial, scientific and agricultural use
  • 05 - Pharmaceutical, veterinary and sanitary products

Goods & Services

[ humanized monoclonal antibody against respiratory syncytial virus for scientific research use ] humanized monoclonal antibody against respiratory syncytial virus for medical clinical use